标题
Pomalidomide: First Global Approval
作者
关键词
Multiple Myeloma, Thalidomide, Bortezomib, Maximum Tolerate Dose, Lenalidomide
出版物
DRUGS
Volume 73, Issue 6, Pages 595-604
出版商
Springer Nature
发表日期
2013-04-09
DOI
10.1007/s40265-013-0047-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- Immunomodulatory drugs in multiple myeloma
- (2013) Swati Andhavarapu et al. Expert Review of Hematology
- Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis
- (2012) A. Dispenzieri et al. BLOOD
- Phase I trial of pomalidomide given for patients with advanced solid tumors
- (2012) Matthew M. Cooney et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
- (2012) Matthew Hoffmann et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Long-term outcome of pomalidomide therapy in myelofibrosis
- (2011) Kebede H. Begna et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
- (2011) M. Q. Lacy et al. BLOOD
- Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice
- (2011) S. E. Meiler et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Lenalidomide
- (2011) Lesley J. Scott et al. DRUGS
- Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy and the activity of pomalidomide on extramedullary myeloma
- (2011) K Detweiler Short et al. LEUKEMIA
- New Immunomodulatory Drugs in Myeloma
- (2011) Martha Q. Lacy Current Hematologic Malignancy Reports
- Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer
- (2011) Robert J. Amato et al. Cancers
- Pomalidomide (POM) In Advanced Corticosteroid-Resistant Chronic Graft-Versus-Host Disease (cGVHD)
- (2010) I. Pusic et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer
- (2010) Jeffrey R. Infante et al. EUROPEAN JOURNAL OF CANCER
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
- (2010) M Q Lacy et al. LEUKEMIA
- Bortezomib
- (2009) Monique P. Curran et al. DRUGS
- Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma
- (2009) Martha Q. Lacy et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation
- (2008) Matthew J. Streetly et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pegylated Liposomal Doxorubicin
- (2008) Greg L Plosker DRUGS
- Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells
- (2008) Laure A. Moutouh-de Parseval et al. JOURNAL OF CLINICAL INVESTIGATION
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- (2008) R A Kyle et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation